

assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than June 14, 1999.

A. Federal Reserve Bank of San Francisco (Maria Villanueva, Manager of Analytical Support, Consumer Regulation Group) 101 Market Street, San Francisco, California 94105-1579:

1. *Bay View Capital Corporation*, San Mateo, California; to acquire Franchise Mortgage Acceptance Company, Los Angeles, California, and thereby engage in extending credit and servicing loans, pursuant to § 225.28(b)(1) of Regulation Y; activities related to extending credit, pursuant to § 225.28(b)(2) of Regulation Y; and leasing personal or real property, pursuant to § 225.28(b)(3) of Regulation Y.

Board of Governors of the Federal Reserve System, May 24, 1999.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 99-13547 Filed 5-26-99; 8:45 am]

BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Notice of Meeting of Consumer Advisory Council

The Consumer Advisory Council will meet on Thursday, June 24, 1999. The meeting, which will be open to public observation, will take place at the Federal Reserve Board's offices in Washington, D.C., in Dining Room E of the Martin Building (Terrace level). The meeting will begin at 8:45 a.m. and is expected to conclude at 1:00 p.m. The Martin Building is located on C Street, Northwest, between 20th and 21st Streets.

The Council's function is to advise the Board on the exercise of the Board's responsibilities under the Consumer

Credit Protection Act and on other matters on which the Board seeks its advice. Time permitting, the Council will discuss the following topics:

Electronic Delivery of Disclosures. The Depository and Delivery Systems and the Consumer Credit Committees will lead a discussion about the electronic delivery of disclosures required under certain consumer financial services and fair lending laws such as the Truth in Lending and Equal Credit Opportunity Acts.

Consumer Financial Privacy. The Depository and Delivery Systems Committee will lead a discussion of current issues on consumer financial privacy matters.

Community Reinvestment Act. The Bank Regulations Committee will lead a discussion on the revised CRA Questions and Answers.

Members Forum. Individual Council members will present views on economic conditions present within their industries or local economies.

Committee Reports. Council committees will report on their work.

Other matters previously considered by the Council or initiated by Council members also may be discussed.

Persons wishing to submit views to the Council regarding any of the above topics may do so by sending written statements to Ann Bistay, Secretary of the Consumer Advisory Council, Division of Consumer and Community Affairs, Board of Governors of the Federal Reserve System, Washington, D.C. 20551. Information about this meeting may be obtained from Ms. Bistay, 202-452-6470.

Telecommunications Device for the Deaf (TDD) users may contact Diane Jenkins, 202-452-3544.

Board of Governors of the Federal Reserve System, May 24, 1999.

Jennifer J. Johnson

Secretary of the Board.

[FR Doc. 99-13550 Filed 5-26-99; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Toxic Substances and Disease Registry

[ATSDR-147]

Availability of Final Toxicological Profile for Mercury

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS).

ACTION: Notice of availability.

SUMMARY: This notice announces the availability of the final updated toxicological profile for mercury completing the eleventh set prepared by ATSDR. The announcement of nine toxicological profiles for the eleventh set was published in the **Federal Register** on March 1, 1999 (64 FR 9999).

FOR FURTHER INFORMATION CONTACT: Ms. Loretta Norman, Division of Toxicology, Agency for Toxic Substances and Disease Registry, Mailstop E-29, 1600 Clifton Road, NE., Atlanta, Georgia 30333, telephone (404) 639-6322.

SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization Act (SARA) (Pub. L. 99-499) amends the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA or Superfund) (42 U.S.C. 9601 *et seq.*) by establishing certain requirements for ATSDR and the Environmental Protection Agency (EPA) with regard to hazardous substances which are most commonly found at facilities on the CERCLA National Priorities List (NPL). Among these statutory requirements is a mandate for the Administrator of ATSDR to prepare toxicological profiles for each substance included on the priority lists of hazardous substances. These lists identified 275 hazardous substances that ATSDR and EPA determined pose the most significant potential threat to human health. The availability of the revised list of the 275 most hazardous substances was announced in the **Federal Register** on November 17, 1997 (62 FR 61332). For prior versions of the list of substances see **Federal Register** notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486).

Notices (62 FR 55816) and (62 FR 55818) announcing the availability of draft toxicological profiles for public review and comment were published in the **Federal Register** on October 28, 1997 (62 FR 55816) with notice of a 90-day public comment period for each profile, starting from the actual release date. Following the close of the comment period, chemical-specific comments were addressed, and where appropriate, changes were incorporated into each profile. The public comments and other data submitted in response to the **Federal Register** notices bear the docket control numbers ATSDR-127 or ATSDR-128. This material is available for public inspection at the Division of

Toxicology, Agency for Toxic Substances and Disease Registry, Building 4, Suite 2400, Executive Park Drive, Atlanta, Georgia, (not a mailing address) between 8:00 a.m. and 4:30 p.m., Monday through Friday, except legal holidays.

Availability

This notice announces the availability of the final updated toxicological profile for mercury completing the eleventh set prepared by ATSDR. The following toxicological profile is now available

through the U.S. Department of Commerce, National Technical Information Service (NTIS), 5285 Port Royal Road, Springfield, Virginia 22161, telephone 1-800-553-6847. There is a charge for these profiles as determined by NTIS.

Toxicological profile	NTIS order No.	CAS No.
MERCURY	PB99-142416	007439-97-6
MERCURIC (II) ACETATE		001600-27-7
MERCURIC (II) SULFIDE		001134-48-5
MERCURIC (I) CHLORIDE		010112-91-1
METHYLMERCURIC CHLORIDE		000115-09-3

Dated: May 20, 1999.

Georgi Jones,

*Director, Office of Policy and External Affairs,
Agency for Toxic Substances and Disease
Registry.*

[FR Doc. 99-13434 Filed 5-26-99; 8:45 am]

BILLING CODE 4163-70-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Announcement Number 99105]

Research Studies to Characterize the Clinical Relevance of HIV Superinfection Notice of Availability of Funds

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 1999 funds for a cooperative agreement program for epidemiologic and laboratory research studies to characterize reinfection with Human Immunodeficiency Virus Type 1 (HIV-1). This program addresses the "Healthy People 2000" priority area of HIV Infection.

The purpose of this program is to characterize the occurrence of reinfection with a second strain of HIV and determine whether reinfection has clinical relevance for the pathogenesis of HIV disease. Specific questions must at least include:

1. Can naturally-occurring reinfection with a second, genotypically distinct strain of HIV-1 be documented after initial infection has been established?
2. (How often?) Does reinfection result in the emergence of a new predominant strain of HIV-1?
3. Is reinfection with a second strain of HIV-1 associated with clinical disease progression, emergence of resistance to antiviral drugs, or other adverse consequences?

B. Eligible Applicants

Applications may be submitted by public and private nonprofit and for-profit organizations and by governments and their agencies; that is, universities, colleges, research institutions, hospitals, other public and private nonprofit and for-profit organizations, State and local governments or their bona fide agents, and federally recognized Indian tribal governments, Indian tribes, or Indian tribal organizations.

Because studies to date suggest that reinfection with a second HIV-1 strain may be rare or difficult to detect, a case-control study design may be most likely to yield expeditious answers to study questions. Funds under this announcement may not be used to establish a prospective cohort. Therefore, successful applicants must demonstrate access to an existing cohort for recruitment of appropriate study subjects for whom stored specimens are available to conduct the necessary retrospective analysis.

C. Availability of Funds

Approximately \$500,000 will be available in FY 1999 to fund approximately 2 awards. It is expected that the average new award will be approximately \$250,000. It is expected that awards will begin on or about September 30, 1999. Awards will be funded for a 12-month budget period within a project period of up to 3 years. Funding estimates may vary. Continuation awards within the project period will be made on the basis of satisfactory progress as evidenced by required reports and the availability of funds.

D. Program Requirements

In conducting activities to achieve the purpose of this program, the recipient will be responsible for the activities listed under Recipient Activities, and CDC will be responsible for conducting activities listed under CDC Activities.

1. Recipient Activities

a. Develop Study Protocol: Design an appropriate study to answer the specific research questions related to HIV-1 reinfection.

b. Identify Study Cohort: Identify a cohort of HIV-infected persons from which eligible study subjects can be recruited, for whom (1) sufficient information is available to document a known or likely re-exposure to a second strain of HIV-1; (2) a clinically significant event such as disease progression or emergence of antiviral drug resistance has been recognized; and (3) suitable stored specimens are available for genotypic analysis of viral strains of HIV-1 before and after occurrence of the clinical event.

c. Conduct Productive and Scientifically Sound Studies: Identify, recruit, obtain informed consent, and enroll study participants as determined by the study protocol and the program requirements. Perform the laboratory tests necessary to characterize viral strains as determined by the study protocol. Ideally, recipients would be able to characterize the HIV-1 strain in the source partner epidemiologically associated with reinfection.

d. Publish the Results of the Study: Upon completion, publish the results of the study. At the completion of the funding period, recipients should optimally prepare at least one manuscript based on the funded research for a peer-reviewed journal. All recipients will provide copies of relevant publications and other significant documents to CDC project co-investigators, and any other local agencies or individuals with a special interest in the research project.

e. Share Data and Specimens: Share data and specimens (when appropriate) with other collaborators to answer the project's specific research questions.

2. CDC Activities

a. Assist in Protocol Development: CDC staff will assist in the development